Hudson Bay Capital Management’s Novo Nordisk NVO Stock Holding History

Hudson Bay Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.6M	Buy	+660,000	New	+$28.4M	0.09%	169
2025 Q4	–	Sell	-426,200	Closed	-$23.6M	–	1438
2025 Q3	$23.6M	Buy	+426,200	New	+$24.9M	0.08%	200
2025 Q2	–	Sell	-250,000	Closed	-$17.4M	–	1577
2025 Q1	$17.4M	Sell	250,000 -300,000	-55%	-$24.8M	0.05%	285
2024 Q4	$47.3M	Buy	+550,000	New	+$59.5M	0.17%	140

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Hudson Bay Capital Management's NVO Position: Q2 2026 in Review

Hudson Bay Capital Management increased its Novo Nordisk (NVO) stake by 484% in Q2 2026, buying an estimated $26M and bringing the position to 730,000 shares worth $35M. The position accounts for 0.1% of the portfolio, ranked #156.

Hudson Bay Capital Management first reported a position in NVO in Q3 2022 and has held it in 10 quarters since. The position peaked at $55.2M in Q4 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Hudson Bay Capital Management held 730,000 shares of Novo Nordisk worth $35M as of Q2 2026.
Hudson Bay Capital Management bought 604,962 Novo Nordisk shares in Q2 2026, an estimated $26M.
Novo Nordisk made up 0.1% of Hudson Bay Capital Management's portfolio in Q2 2026, its #156 holding.
Hudson Bay Capital Management first reported a position in Novo Nordisk in Q3 2022 and has held it in 10 quarters since.
Hudson Bay Capital Management's Novo Nordisk position peaked at $55.2M in Q4 2024.
1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.